Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.53
-$0.11(-0.75%)
At close: 4:00 PM EDT
$14.53
-$0.11(-0.75%)
Day’s Range― - ―
52-Week Range$5.78 - $19.40
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.36M
Market Cap
$393.10M
Enterprise Value$604.41
Total Cash (Recent Filing)$118.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 18, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding26,525,160
10 Day Avg. Volume1,158,957
30 Day Avg. Volume1,364,040
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.67Price Target Upside159.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative, Largely Debt-free Balance SheetA negligible debt load and a sharply expanded equity base provide durable financial flexibility for a development-stage biotech. This reduces interest burden, lowers default risk and improves the company's ability to finance pivotal trial completion or commercialization via equity or partnerships without immediate refinancing pressure.
Secured Long-term Supply And Licensing StabilityA long-term manufacturing agreement and a license extension materially reduce commercial execution risk if the drug is approved. Secure supply, defined cost-sharing and extended regulatory timelines lower operational hurdles and enable more predictable planning for scale-up and regulatory interactions over years.
Powered Phase 3 Registrational Readout With High-profile VenueA well-powered, registrational Phase 3 with a late-breaking presentation at a major cardiology congress is a durable operational milestone. Positive results would establish clinical efficacy, materially change regulatory prospects and create sustainable commercial optionality in an area with unmet need and no approved therapies.
Bears Say
Pre-revenue With Rapidly Widening LossesPersistent zero revenue and materially expanding net losses reflect a business still fully in development. Over the medium term this depletes capital, constrains strategic optionality and increases dependence on external financing or partnerships to sustain operations absent successful clinical or licensing outcomes.
High And Worsening Operating Cash BurnEscalating negative operating cash flow indicates significant ongoing funding needs. Even with prior capital raises, sustained burn increases the likelihood of future dilutive financings or restrictive partnering terms, constraining strategic choices and raising execution risk until a clinical or commercial inflection.
Concentrated Single-asset Development ProfileReliance on a single late-stage program concentrates binary clinical and regulatory risk: a negative Phase 3 outcome would materially impair the company's value and strategic prospects. A small development footprint magnifies operational risk and limits diversification of revenue or pipeline resilience over the medium term.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $5.78 and its highest was $19.40 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $393.10M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 18 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on May 12, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.047.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 26,525,160 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went up 1.841%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (159.23% Upside)
$37.67 (159.23% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
167.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.92%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$37.67
▲(159.23% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.16% Insiders
12.05% Mutual Funds
0.15% Other Institutional Investors
77.68% Public Companies and
Individual Investors